4SC AG
https://www.4sc.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From 4SC AG
Boston Scientific TheraSphere Liver Cancer Treatment Succeeds In EPOCH Trial
Results showed that patients were less likely to exhibit disease progression, or die, following treatment with beta-emitted microspheres.
Finance Watch: A Summer Slowdown? Not For Venture Capital Mega-Rounds
Private Company Edition: The latest $100m-plus VC financings include $112.5m for PepGen, Deep Genomics’ $180m series C round and a $166m series D for Rakuten Medical. Also, Lumira Ventures raised a $220m fourth fund and will manage a separate $35m fund backed by Angelini Pharma.
Sarepta’s Next-Gen DMD Drug SRP-5051 Shows Advantages, But Safety Concerns Too
The next-generation DMD drug showed dramatic improvement on exon dystrophin and exon skipping, but small numbers and adverse events give pause.
UK’s NICE Backs Two Microsphere Products For Liver Cancer But Says No To Another
Health technology assessment body NICE has now recommended that selective internal radiation therapy can be used on England’s National Health Service for treating advanced liver cancer.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- 4SC Discovery GmbH